{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T03:35:55Z","timestamp":1781840155102,"version":"3.54.5"},"reference-count":35,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Generalized pustular psoriasis (GPP) is a rare inflammatory skin disease with a considerable clinical burden. In the Effisayil\u2122 1 study, spesolimab, an anti\u2010interleukin\u201036 receptor monoclonal antibody, demonstrated efficacy in treating GPP flares.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate patient\u2010reported outcomes (PROs) of patients with GPP who were treated with intravenous (IV) spesolimab 900\u2009mg in the Effisayil\u2122 1 study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Fifty\u2010three patients presenting with a GPP flare were randomized (2:1) to receive a single dose of IV spesolimab 900\u2009mg or placebo and were followed for 12\u2009weeks. Four PROs (pain visual analogue scale [pain VAS]; Functional Assessment of Chronic Illness Therapy\u2013Fatigue [FACIT\u2013Fatigue]; Dermatology Life Quality Index [DLQI]; and Psoriasis Symptom Scale [PSS]) were assessed throughout the 12\u2010week study. Minimal clinically important differences (MCIDs) were defined. All data are reported descriptively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In patients who received spesolimab, improvements from baseline (median [Q1, Q3]) were observed in pain VAS (\u221221.3 [\u221255.3, \u22123.1]), FACIT\u2013Fatigue (7.0 [1.0, 20.0]), DLQI (\u22122.5 [\u22128.0, 1.0]) and PSS (\u22124.0 [\u22127.0, 0.0]) within 1\u00a0week of treatment. These improvements were sustained over 12\u2009weeks and corresponded to the achievement of MCIDs at Week 1, which were also sustained over 12\u2009weeks. Patients in the placebo arm experienced improvements in PROs and achievement of MCIDs after receipt of open\u2010label spesolimab at Week 1.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Patients with a GPP flare treated with spesolimab achieved improvements in PROs by Week 1, which were sustained for 12\u2009weeks, and achieved MCIDs as early as Week 1.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.18820","type":"journal-article","created":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T13:10:04Z","timestamp":1671282604000},"page":"730-736","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Spesolimab improves patient\u2010reported outcomes in patients with generalized pustular psoriasis: Results from the Effisayil 1 study"],"prefix":"10.1111","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7059-632X","authenticated-orcid":false,"given":"Alexander A.","family":"Navarini","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergy University Hospital Basel  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg C.","family":"Prinz","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy University Clinics, Ludwig\u2010Maximilian\u2010University of Munich  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-3754","authenticated-orcid":false,"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Geriatric and Environmental Dermatology Nagoya City University Graduate School of Medical Sciences  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1498-1474","authenticated-orcid":false,"given":"Tsen\u2010Fang","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Dermatology National Taiwan University Hospital and National Taiwan University College of Medicine  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuelle\u2010Anne","family":"Viguier","sequence":"additional","affiliation":[{"name":"Department of Dermatology H\u00f4pital Robert Debr\u00e9  Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim (China) Investment Co., Ltd  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Thoma","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH  Biberach Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mogana","family":"Sivalingam","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim International GmbH  Ingelheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111563"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043666"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1648209"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00493-0"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14386"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14523"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12070"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14814"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00663-y"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.01.032"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13306"},{"key":"e_1_2_11_13_1","unstructured":"Abbvie.Abbvie announces first regulatory approval of SKYRIZI\u2122 (risankizumab) for the treatment of plaque psoriasis generalized pustular psoriasis and erythrodermic psoriasis and psoriatic arthritis in Japan.2019."},{"key":"e_1_2_11_14_1","first-page":"815","article-title":"Pustular psoriasis (generalized) clinical guidelines 2010","volume":"120","author":"Iwatsuki KT","year":"2010","journal-title":"Jpn J Dermatol"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12773"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13622"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14294"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14318"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14702"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12610"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013068"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2017.1353853"},{"key":"e_1_2_11_23_1","unstructured":"U.S. FDA approves first treatment option for generalized pustular psoriasis flares in adults.2021[cited 2022 Jun 1]. Available from:https:\/\/www.boehringer\u2010ingelheim.com\/human\u2010health\/skin\u2010diseases\/fda\u2010approves\u2010first\u2010gpp\u2010flare\u2010treatment"},{"key":"e_1_2_11_24_1","unstructured":"ClinicalTrials.gov.NCT03619902. [cited 2022 Jun 1]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03619902"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-020-00219-4"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1603361"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1709612"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08205.x"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10139.x"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1159\/000237871"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3388"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1159\/000365390"},{"key":"e_1_2_11_33_1","first-page":"811","article-title":"Validation of the Functional Assessment of Chronic Illness Therapy Fatigue scale relative to other instrumentation in patients with rheumatoid arthritis","volume":"32","author":"Cella D","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1197\/S1069-6563(03)00372-5"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-016-0196-6"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90005-6"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18820","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.18820","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T12:12:20Z","timestamp":1695211940000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.18820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1111\/jdv.18820"],"URL":"https:\/\/doi.org\/10.1111\/jdv.18820","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,23]]},"assertion":[{"value":"2022-06-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}